Abstract:A previous phase III randomized trial improved overall survival of patients with advanced or relapsed squamous cell lung carcinoma, compared with cisplatin plus docetaxel. However, evaluation of nedaplatin plus docetaxel’s effect on progression free survival (PFS) and time to progression (TTP) was limited. To compare the efficacy and safety of nedaplatin plus docetaxel and cisplatin plus docetaxel. In this randomized, open-label, multicenter trial, patients diagnosed with advanced or relapsed squamous cell carcinoma pathologically or cytologically were enrolled in China. All the patients have no previous oncology medication. Patients were randomly assigned (1:1) to 80 mg/m2 nedaplatin and 75 mg/m2 docetaxel intravenously, or 75 mg/m2 cisplatin and 75 mg/m2 docetaxel, every 3 weeks for four cycles. The primary end points was PFS. Secondary endpoints included TTP and best overall response. The efficacy endpoint were analyzed in the intention-to-treat set and in the per protocol set. (Clinical trial number: NCT02088515; Funding: Jiangsu Simcere Pharmaceutical Co., Ltd.). From December 2013 to December 2015, 286 patients were randomly assigned. Two hundred and eighty patients were included in the modified intention-to-treat analysis (141 in the nedaplatin group and 139 in the cisplatin group). In the intention-to-treat analysis set, median PFS was 4.63 months (95% confidence interval (CI), 4.43-5.10) in the nedaplatin group and 4.23 months (95% CI, 3.37-4.53) in the cisplatin group. PFS did not differ significantly between two groups (log-rank test, p =0.056). In per protocol set, PFS was significantly longer in the nedaplatin group (median 4.63 months, 95% CI, 4.43-5.10) than in the cisplatin group (median 4.27 months, 95% CI, 3.37-4.53; hazard ratio 0.760, 95% CI 0.585-0.989; p=0.039, log-rank test). Best overall response and TTP were improved in nedaplatin group than in cisplatin group (p= 0.002, median 4.57(4.30-4.80) vs 3.67(3.13-4.43) p= 0.020, respectively) in the intention-to-treat analysis set. Grade III or IV adverse events was more frequent in the cisplatin group than in the nedaplatin group (46 of 141 patients in the nedaplatin group and 62 of 139 in the cisplatin group, p=0.039). Grade 3 or worse nausea (0 vs 7) and fatigue (1 vs 3) were more frequent in the cisplatin group than in the nedaplatin group. There was no significant difference of PFS between cisplatin group and nedaplatin group. However, more adverse events was observed in the cisplatin group than in the nedaplatin group. Nedaplatin plus docetaxel could be a new treatment option for advanced or relapsed squamous cell lung cancer.

Comparison of the Clinical Effect of Cisplatin combined with Docetaxel, Pemetrexed and Gemcitabine on Advanced Lung Adenocarcinoma

The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Efficacy and safety of pemetrexed in advanced primary adenocarcinoma of lung

Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].

MA 03.03 Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung

Pemetrexed plus platinum in non-small cell lung cancer:a Meta analysis of randomized controlled trials

Comparisons of two chemoradiotherapy regimens for locally advanced non-squamous and non-small cell lung cancer

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Comparison of gefitinib and platinum-based chemotherapy and only platinum-based chemotherapy to treat lung adenocarcinoma

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer

Randomized trial of gemcitabine plus cisplatin versus paclitaxel plus cisplatin in treating advanced non-small cell lung cancer

Meta-analysis on platinum plus pemetrexed or docetaxel in treatment of non-small cell lung cancer

First-line Chemotherapy of Docetaxel/Cisplatin for Advanced Non-small Cell Lung Cancer